CABA
Cabaletta Bio Inc
NASDAQ: CABA · HEALTHCARE · BIOTECHNOLOGY
$3.63
-7.41% today
Updated 2026-06-05
Market cap
$572.32M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.78
Dividend yield
—
52W range
$1 – $4
Volume
3.5M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-5.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$13.38
+268.60%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy7 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.26x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -5.79 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-42.56M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-51.81M | $-67.67M | $-115.86M | $-167.86M | $-43.52M |
| EPS | — | — | — | — | $-1.78 |
| Free cash flow | $-48.83M | $-54.24M | $-90.43M | $-132.31M | $-42.56M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-02 | NICHTBERGER, STEVEN | Buy | 674,000 | — |
| 2026-03-02 | MARDA, ANUP | Buy | 225,000 | — |
| 2026-03-02 | GERARD, MICHAEL | Buy | 175,000 | — |
Peer comparison
Smart narrative
Cabaletta Bio Inc trades at $3.63. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -5.79, it sits in the distress.
Frequently asked questions
What is Cabaletta Bio Inc's stock price?
Cabaletta Bio Inc (CABA) trades at $3.63.
Is Cabaletta Bio Inc overvalued?
Cabaletta Bio Inc carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Cabaletta Bio Inc (CABA)?
The 12-month analyst consensus target is $13.38, about 268.6% above the current $3.63. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Cabaletta Bio Inc's Altman Z-Score is -5.79, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-169.82%
Beta3.23
50D MA$3.30
200D MA$2.67
Shares out0.16B
Float0.14B
Short ratio—
Avg volume3.5M
Performance
1 week+0.00%
1 month-1.81%
3 months+6.21%
YTD+48.40%
1 year—
3 years—
5 years—